Insider Sale: Director at $ADMA Sells 10,000 Shares

Director Jerrold B Grossman sold 10,000 shares of ADMA Biologics ($ADMA) on June 9, 2025, for approximately $213,100, representing 2.0% of their holdings; he retains 478,194 shares. Over the past six months, ADMA insiders have executed nine sales and zero purchases, with CEO Adam S. Grossman accounting for the majority of sales at $1.26M. Institutional investors show mixed sentiment, with State Street Corp and Nuveen Asset Management reducing their positions significantly in Q1 2025, while UBS Group AG and Ranger Investment Management, L.P. increased their holdings.

Analysis

ADMA Biologics ($ADMA) has seen notable insider selling activity, underscored by Director Jerrold B Grossman's recent sale of 10,000 shares for approximately $213,100, reducing his holdings by 2.0% yet leaving him with 478,194 shares. This transaction aligns with a broader trend over the past six months, where ADMA insiders, including President and CEO Adam S. Grossman who sold 63,000 shares for an estimated $1.26 million, have conducted nine sales and zero purchases. Such consistent selling by senior management often signals caution. Institutional activity presents a more bifurcated picture: while 186 institutions increased their ADMA holdings in the most recent quarter, 196 reduced theirs. Significant divestitures include State Street Corp's disposal of 3.43 million shares (-23.1%) in Q1 2025 and Nuveen Asset Management's reduction of 2.03 million shares (-30.8%) in Q4 2024. Conversely, UBS Group AG increased its stake by 1.81 million shares (+180.6%) and Ranger Investment Management initiated or significantly boosted its position by 1.60 million shares in Q1 2025. This divergence, alongside the negative insider cues, contributes to an overall 'moderately negative' sentiment (-0.5) for $ADMA.

Key Decisions for Investors

• Investors should critically evaluate the persistent pattern of insider sales at $ADMA, particularly from senior executives, as a potential indicator of their outlook on the company's near-term prospects.
• The divergent institutional flows, with some large funds significantly reducing positions while others make substantial new investments, warrant a careful assessment of the specific theses driving these opposing actions.
• Consider maintaining a cautious approach towards $ADMA, and monitor for any shifts in insider behavior or institutional sentiment that could alter the current risk-reward profile, especially in light of the 'moderately negative' sentiment score.